Long-Term Trajectories of High-Sensitivity C-Reactive Protein Level Among Patients with Acute Heart Failure

References

• Groenewegen A, Rutten FH, Mosterd A, et al. Epidemiology of heart failure. Eur J Heart Fail. 2020;22(8):1342–1356. doi:10.1002/ejhf.1858
   PubMed Web of Science ®Google Scholar
• Wang H, Chai K, Du M, et al. Prevalence and incidence of heart failure among urban patients in china: a national population-based analysis. Circ Heart Fail. 2021;14(10):e008406. doi:10.1161/CIRCHEARTFAILURE.121.008406
   PubMed Web of Science ®Google Scholar
• Tromp J, Westenbrink BD, Ouwerkerk W, et al. Identifying pathophysiological mechanisms in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol. 2018;72(10):1081–1090. doi:10.1016/j.jacc.2018.06.050
   PubMed Web of Science ®Google Scholar
• Back M, Yurdagul A, Tabas I, et al. Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities. Nat Rev Cardiol. 2019;16(7):389–406. doi:10.1038/s41569-019-0169-2
   PubMed Web of Science ®Google Scholar
• Williams JW, Huang LH, Randolph GJ. Cytokine circuits in cardiovascular disease. Immunity. 2019;50(4):941–954. doi:10.1016/j.immuni.2019.03.007
   PubMed Web of Science ®Google Scholar
• Frangogiannis NG. The inflammatory response in myocardial injury, repair, and remodelling. Nat Rev Cardiol. 2014;11(5):255–265. doi:10.1038/nrcardio.2014.28
   PubMed Web of Science ®Google Scholar
• Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2014;11(9):507–515. doi:10.1038/nrcardio.2014.83
   PubMed Web of Science ®Google Scholar
• Murphy SP, Kakkar R, McCarthy CP, et al. Inflammation in heart failure: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(11):1324–1340. doi:10.1016/j.jacc.2020.01.014
   Web of Science ®Google Scholar
• Pellicori P, Zhang J, Cuthbert J, et al. High-sensitivity C-reactive protein in chronic heart failure: patient characteristics, phenotypes, and mode of death. Cardiovasc Res. 2020;116(1):91–100. doi:10.1093/cvr/cvz198
   PubMed Web of Science ®Google Scholar
• Anand IS, Latini R, Florea VG, et al. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation. 2005;112(10):1428–1434. doi:10.1161/CIRCULATIONAHA.104.508465
   PubMed Web of Science ®Google Scholar
• Kalogeropoulos AP, Tang WH, Hsu A, et al. High-sensitivity C-reactive protein in acute heart failure: insights from the ASCEND-HF trial. J Card Fail. 2014;20(5):319–326. doi:10.1016/j.cardfail.2014.02.002
   Web of Science ®Google Scholar
• Lourenco P, Pereira J, Ribeiro A, et al. C-reactive protein decrease associates with mortality reduction only in heart failure with preserved ejection fraction. J Cardiovasc Med. 2019;20(1):23–29. doi:10.2459/JCM.0000000000000726
   Google Scholar
• Boulogne M, Sadoune M, Launay JM, et al. Inflammation versus mechanical stretch biomarkers over time in acutely decompensated heart failure with reduced ejection fraction. Int J Cardiol. 2017;226:53–59. doi:10.1016/j.ijcard.2016.10.038
   PubMed Web of Science ®Google Scholar
• Milo-Cotter O, Cotter-Davison B, Lombardi C, et al. Neurohormonal activation in acute heart failure: results from VERITAS. Cardiology. 2011;119(2):96–105. doi:10.1159/000330409
   Web of Science ®Google Scholar
• Vaz-Luis I, Di Meglio A, Havas J, et al. Long-term longitudinal patterns of patient-reported fatigue after breast cancer: a group-based trajectory analysis. J Clin Oncol. 2022;40:Jco2101958.
   Web of Science ®Google Scholar
• Pierce M, McManus S, Hope H, et al. Mental health responses to the COVID-19 pandemic: a latent class trajectory analysis using longitudinal UK data. Lancet Psychiatry. 2021;8(7):610–619. doi:10.1016/S2215-0366(21)00151-6
   PubMed Web of Science ®Google Scholar
• Joo YS, Kim HW, Nam KH, et al. Association between longitudinal blood pressure trajectory and the progression of chronic kidney disease: results from the KNOW-CKD. Hypertension. 2021;78(5):1355–1364. doi:10.1161/HYPERTENSIONAHA.121.17542
   Web of Science ®Google Scholar
• Huang X, Yu Y, Li X, et al. The China Patient-centred Evaluative Assessment of Cardiac Events (PEACE) prospective heart failure study design. BMJ Open. 2019;9(2):e025144. doi:10.1136/bmjopen-2018-025144
   Web of Science ®Google Scholar
• Heart Failure Group of Chinese Society of Cardiology of Chinese Medical Association; Chinese Heart Failure Association of Chinese Medical Doctor Association; Editorial Board of Chinese Journal of Cardiology. Chinese guidelines for the diagnosis and treatment of heart failure 2018. Zhonghua Xin Xue Guan Bing Za Zhi. 2018;46(10):760–789. doi:10.3760/cma.j.issn.0253-3758.2018.10.004
   PubMedGoogle Scholar
• McDonagh TA, Metra M, Adamo M, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;2021:1787–1847.
   Google Scholar
• Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol. 2022;79(17):1757–1780. doi:10.1016/j.jacc.2021.12.011
   PubMed Web of Science ®Google Scholar
• Zhu B, Liu WH, Yu DR, et al. The association of low hemoglobin levels with IgA nephropathy progression: a two-center cohort study of 1828 cases. Am J Nephrol. 2020;51(8):624–634. doi:10.1159/000508770
   PubMed Web of Science ®Google Scholar
• Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol. 2006;17(10):2937–2944. doi:10.1681/ASN.2006040368
   PubMed Web of Science ®Google Scholar
• Wang TJ, Wollert KC, Larson MG, et al. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation. 2012;126(13):1596–1604. doi:10.1161/CIRCULATIONAHA.112.129437
   PubMed Web of Science ®Google Scholar
• Haynes R, Jiang L, Hopewell JC; HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34(17):1279–1291. doi:10.1093/eurheartj/eht055
   PubMed Web of Science ®Google Scholar
• Hu D, Liu J, Zhang L, et al. Health status predicts short- and long-term risk of composite clinical outcomes in acute heart failure. JACC Heart Fail. 2021;9(12):861–873. doi:10.1016/j.jchf.2021.06.015
   Web of Science ®Google Scholar
• Gunderson EP, Greenberg M, Nguyen-Huynh MN, et al. Early pregnancy blood pressure patterns identify risk of hypertensive disorders of pregnancy among racial and ethnic groups. Hypertension. 2022;79(3):599–613. doi:10.1161/HYPERTENSIONAHA.121.18568
   Web of Science ®Google Scholar
• Jones RH. Bayesian information criterion for longitudinal and clustered data. Stat Med. 2011;30(25):3050–3056. doi:10.1002/sim.4323
   Web of Science ®Google Scholar
• Bengtson AM, Pence BW, Powers KA, et al. Trajectories of depressive symptoms among a population of HIV-infected men and women in routine HIV care in the United States. AIDS Behav. 2018;22(10):3176–3187. doi:10.1007/s10461-018-2109-2
   Web of Science ®Google Scholar
• Nagin DS, Odgers CL. Group-based trajectory modeling in clinical research. Annu Rev Clin Psycho. 2010;6:109–138. doi:10.1146/annurev.clinpsy.121208.131413
   PubMed Web of Science ®Google Scholar
• Austin PC, Lee DS, Fine JP; Introduction to the analysis of survival data in the presence of competing risks. Circulation. 2016;133(6):601–609. doi:10.1161/CIRCULATIONAHA.115.017719
   PubMed Web of Science ®Google Scholar
• Nagin DS, Jones BL, Passos VL, et al. Group-based multi-trajectory modeling. Stat Methods Med Res. 2018;27(7):2015–2023. doi:10.1177/0962280216673085
   PubMed Web of Science ®Google Scholar
• Mentz RJ, O’Connor CM. Pathophysiology and clinical evaluation of acute heart failure. Nat Rev Cardiol. 2016;13(1):28–35. doi:10.1038/nrcardio.2015.134
   Web of Science ®Google Scholar
• Epelman S, Liu PP, Mann DL. Role of innate and adaptive immune mechanisms in cardiac injury and repair. Nat Rev Immunol. 2015;15(2):117–129. doi:10.1038/nri3800
   PubMed Web of Science ®Google Scholar
• Van Linthout S, Tschöpe C. Inflammation - cause or consequence of heart failure or both? Curr Heart Fail Rep. 2017;14(4):251–265. doi:10.1007/s11897-017-0337-9
   PubMedGoogle Scholar
• Dick SA, Epelman S. Chronic heart failure and inflammation: what do we really know? Circ Res. 2016;119(1):159–176. doi:10.1161/CIRCRESAHA.116.308030
   PubMed Web of Science ®Google Scholar
• Matsumoto M, Tsujino T, Lee-Kawabata M, et al. Serum interleukin-6 and C-reactive protein are markedly elevated in acute decompensated heart failure patients with left ventricular systolic dysfunction. Cytokine. 2010;49(3):264–268. doi:10.1016/j.cyto.2009.11.006
   Web of Science ®Google Scholar
• Nishimoto Y, Kato T, Morimoto T, et al. C-reactive protein at discharge and 1-year mortality in hospitalised patients with acute decompensated heart failure: an observational study. BMJ Open. 2020;10(12):e041068. doi:10.1136/bmjopen-2020-041068
   Web of Science ®Google Scholar
• Minami Y, Kajimoto K, Sato N, et al. C-reactive protein level on admission and time to and cause of death in patients hospitalized for acute heart failure. Eur Heart J Qual Care Clin Outcomes. 2017;3(2):148–156. doi:10.1093/ehjqcco/qcw054
   Google Scholar
• Nian M, Lee P, Khaper N, et al. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res. 2004;94(12):1543–1553. doi:10.1161/01.RES.0000130526.20854.fa
   PubMed Web of Science ®Google Scholar
• Briasoulis A, Androulakis E, Christophides T, et al. The role of inflammation and cell death in the pathogenesis, progression and treatment of heart failure. Heart Fail Rev. 2016;21(2):169–176. doi:10.1007/s10741-016-9533-z
   PubMed Web of Science ®Google Scholar
• Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107(25):3133–3140. doi:10.1161/01.CIR.0000077913.60364.D2
   PubMed Web of Science ®Google Scholar
• Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004;109(13):1594–1602. doi:10.1161/01.CIR.0000124490.27666.B2
   PubMed Web of Science ®Google Scholar
• Ò M, Takagi K, Davison BA, et al. Effect of systemic corticosteroid therapy for acute heart failure patients with elevated C-reactive protein. ESC Heart Fail. 2022. doi:10.1002/ehf2.13926
   Web of Science ®Google Scholar
• Deftereos S, Giannopoulos G, Panagopoulou V, et al. Anti-inflammatory treatment with colchicine in stable chronic heart failure: a prospective, randomized study. JACC Heart Fail. 2014;2(2):131–137. doi:10.1016/j.jchf.2013.11.006
   PubMed Web of Science ®Google Scholar